Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; vaccines administered past the expiration date.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (vaccines administered past the expiration date.) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 060H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (vaccines administered past the expiration date.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (vaccines administered past the expiration date.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (vaccines administered past the expiration date.).    This is case is for Patient 1 of 13 patients.  No concomitant medications were reported.   It was reported that as per the provider the vaccines were stored in a standard freezer (15°C to -25°C). Their temperatures were Max: -24C and Min: -23C. It was reported that Moderna COVID-19 Vaccine with Lot number: 060H21A was received on 27-Dec-2020 with expiration date as 28-Mar-2022 but the Date of administration was 11-Apr-2022 with doses of 13.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2023-728249, US-MODERNATX, INC.-MOD-2023-728254, US-MODERNATX, INC.-MOD-2023-728251, US-MODERNATX, INC.-MOD-2023-728256, US-MODERNATX, INC.-MOD-2023-728260, US-MODERNATX, INC.-MOD-2023-728264, US-MODERNATX, INC.-MOD-2023-728266, US-MODERNATX, INC.-MOD-2023-728268, US-MODERNATX, INC.-MOD-2023-728269, US-MODERNATX, INC.-MOD-2023-728273, US-MODERNATX, INC.-MOD-2023-728280, US-MODERNATX, INC.-MOD-2023-728275 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 07-Jun-2023: Follow up received with no significant information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728251:Patient no 02 US-MODERNATX, INC.-MOD-2023-728254:Master Case(Patient 1) US-MODERNATX, INC.-MOD-2023-728249:Master Case(Patient 1) US-MODERNATX, INC.-MOD-2023-728256:Master Case(Patient 1) US-MODERNATX, INC.-MOD-2023-728266:(13 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728269:3rd patient Out of 13 US-MODERNATX, INC.-MOD-2023-728260:(11 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728264:(12 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728268:( 5 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728273:(6 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728280:( 7 patient Out of 13) US-MODERNATX, INC.-MOD-2023-728275:4th Patient Out of 13